Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

B7. 1-CD19scFv fusion gene engineering albumen for treating B lymphocyte leukemia and lymph tumour and use thereof

A b7.1-cd19scfv, B lymphocyte technology, applied in the direction of genetic engineering, hybrid immunoglobulin, plant genetic improvement, etc. Promoting clonal proliferation, prolonging survival, significant immunotherapeutic effect

Inactive Publication Date: 2007-02-28
INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Loss of the second signal results in T cell "immunocompetence," preventing clonal expansion of tumor-specific cytotoxic T cells (CTLs)
[0006] Studies have shown that the expression of immune co-stimulatory molecule B7.1 on the surface of ALL leukemia cells is reduced or even absent, resulting in the inability of leukemia cells to be effectively recognized and killed by cytotoxic T cells (CTL)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • B7. 1-CD19scFv fusion gene engineering albumen for treating B lymphocyte leukemia and lymph tumour and use thereof
  • B7. 1-CD19scFv fusion gene engineering albumen for treating B lymphocyte leukemia and lymph tumour and use thereof
  • B7. 1-CD19scFv fusion gene engineering albumen for treating B lymphocyte leukemia and lymph tumour and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] The B7.1-CD19scFv fusion genetically engineered protein for the treatment of B lymphocytic leukemia and lymphoma of the present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments:

[0033] 1. Cloning of Human Self-Cell Surface Antigen B7.1 Gene

[0034] 1. The human B7.1 differentiation antigen cDNA sequence was searched from the GenBank database of the US National Library of Medicine website (http: / / www.ncbi.nlm.nih.gov / entrez), and primers were designed with the help of primer design software primer 3.

[0035] Primers for amplifying the extracellular region of B7.1:

[0036] primer-sen: 5'-ccg gaattc ggtgttatccacgtgac-3'

[0037] EcoRI

[0038] Antisen: 5'-ccc aagctt tgtattccagttgaagg-3'

[0039] Hind III

[0040] 2. RT-PCR amplification of human B7.1 gene

[0041] 2.1 Extract total RNA from B lymphocytes expressing B7.1.

[0042] (1) Take about 10 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a B7.1-CD19scFv merge gene engineering protein and usage to treat B lymphocyte leukosis, lymph tumor, which comprises the following parts: human B7.1 external cell area, antihuman CD19 monoclonal antibody heavy chain and light chain variable area gene.

Description

technical field [0001] The invention relates to a fusion genetic engineering protein, especially a B7.1-CD19scFv fusion genetic engineering protein for treating B lymphocytic leukemia and lymphoma and its application. Background technique [0002] The immune response mediated by tumor-specific T cells is the main means for the body to eliminate tumor cells. In a normal immune response, antigen-specific T cells need to be stimulated by at least two signals to proliferate and generate an immune response to the antigen. The first signal is antigen-specific and is mediated by T-cell receptors (TCR) and MHC class I or II molecules that bind specific antigens, and the second signal is by antigen-presenting cells (APCs) or other It is mediated by the reaction between co-stimulatory molecules (such as B7 molecules) on the cell surface and T cell surface molecules (such as CD28). Tumor cells escape the body's immune surveillance by down-regulating the expression of molecules involve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/46C12N15/13C12N15/62C12N15/63A61K39/395A61P35/00A61P35/02
Inventor 王敏王建祥陈森陈礼平饶青疗小龙
Owner INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products